Effects of Antithymocyte Globulin, Basiliximab, and Induction-Free Treatment in Living Donor Kidney Transplant Recipients on Tacrolimus-Based Immunosuppression

Basit Öğe Kaydı
dc.authoridKaraca, Cebrail/0000-0003-0969-7708
dc.contributor.authorSonmez, Ozge
dc.contributor.authorOzcan, Seyda Gul
dc.contributor.authorKaraca, Cebrail
dc.contributor.authorAtli, Zeynep
dc.contributor.authorDincer, Mevlut Tamer
dc.contributor.authorTrabulus, Sinan
dc.contributor.authorSeyahi, Nurhan
dc.date.accessioned2025-03-23T19:25:32Z
dc.date.available2025-03-23T19:25:32Z
dc.date.issued2024
dc.departmentSinop Üniversitesi
dc.description.abstractObjectives: Induction treatment in renal transplant is associated with better graft survival. However, intensified immunosuppression is known to cause unwanted side effects such as infection and malignancy. Furthermore, the effects of the routine use of immunosuppressants in low -risk kidney transplant recipients are still not clear. In this study, we assessed the first -year safety and efficacy of induction treatment. Materials and Methods: We examined first living donor kidney transplant patients who were on tacrolimusbased immunosuppression therapy. We formed 3 groups according to the induction status: antithymocyte globulin induction, basiliximab induction, and no induction. We collected outcome data on delayed graft function, graft loss, creatinine levels, estimated glomerular filtration rates, acute rejection episodes, hospitalization episodes, and infection episodes, including cytomegalovirus infection and bacterial infections. Results: We examined a total of 126 patients (age 35 +/- 12 years; 65% male). Of them, 25 received antithymocyte globulin, 52 received basiliximab, and 49 did not receive any induction treatment. We did not observe any statistically significant difference among the 3 groups in terms of acute rejection episodes, delayed graft function, and first -year graft loss. The estimated glomerular filtration rates were similar among the groups. Overall bacterial infectious complications and cytomegalovirus infection showed similar prevalence among all groups. Hospitalization was less common in the induction -free group. Conclusions: In low -risk patients, induction -free regimens could be associated with a better safety profile without compromising graft survival. Therefore, induction treatment may be disregarded in first living donor transplant patients who receive tacrolimusbased triple immunosuppression treatment.
dc.identifier.doi10.6002/ect.2023.0010
dc.identifier.endpage276
dc.identifier.issn1304-0855
dc.identifier.issn2146-8427
dc.identifier.issue4
dc.identifier.pmid38742317
dc.identifier.scopus2-s2.0-85192908612
dc.identifier.scopusqualityQ3
dc.identifier.startpage270
dc.identifier.urihttps://doi.org/10.6002/ect.2023.0010
dc.identifier.urihttps://hdl.handle.net/11486/4490
dc.identifier.volume22
dc.identifier.wosWOS:001253628600004
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBaskent Univ
dc.relation.ispartofExperimental and Clinical Transplantation
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250323
dc.subjectInduction treatment
dc.subjectLiving donor transplantation
dc.subjectRenal transplantation
dc.titleEffects of Antithymocyte Globulin, Basiliximab, and Induction-Free Treatment in Living Donor Kidney Transplant Recipients on Tacrolimus-Based Immunosuppression
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu